Trial Profile
A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1 Adjuvant Against Fluzone Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Seasonal-influenza-nanoparticle-vaccine-Novavax (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novavax
- 11 Apr 2023 The protocol has been amended as above- 1) New primary endpoint has been added -Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses. Time frames of adverse events has been differentiated.2)status has been completed.
- 11 Apr 2023 Status changed from active, no longer recruiting to completed.
- 20 Apr 2022 According to a Novavax media release, data were presented at the World Vaccine Congress (WVC).